MSD Korea to release new anesthetic

Published: 2013-02-01 06:56:00

Updated: 2013-02-01 06:56:00

MSD Korea announced Wednesday that it will launch Bridion (sugammadex) injection, the first and only selective relaxant binding agent (SRBA), in Korea from Feb. 1.

Bridion is indicated for routine reversal of the commonly used muscle relaxants rocuronium or vecuronium and for immediate reversa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK